Literature DB >> 20580757

A comparative study of morphine stimulation and biphalin inhibition of human glioblastoma T98G cell proliferation in vitro.

Marzena Lazarczyk1, Ewa Matyja, Andrzej W Lipkowski.   

Abstract

Biphalin is a new type of opioid peptide analog with high analgesic potency that is over 1000-fold greater than morphine. Because of its less addictive nature, biphalin has been suggested as a prospective new analgesic drug. Its high analgesic activity may be related to synergic interaction with all three types of opioid receptors (mu, delta, and kappa). Earlier data implicating involvement of opioid receptors, particularly MOR (mu opioid receptor) and KOR (kappa opioid receptor), in cell cycle regulation prompted us to investigate the effect of biphalin and morphine on human glioma T98G cell proliferation in vitro. We have documented an inhibitory effect of biphalin on tumor cell growth related to a decreased proliferation rate, decline of cell ability to form colonies, and modulation of the Ki-67 proliferation index. Morphine displayed the opposite effect and triggered stimulation of T98G cell proliferation. Our experiments have shown that biphalin might constitute an alternative solution for morphine application in anti-pain and anti-cancer therapy. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20580757     DOI: 10.1016/j.peptides.2010.05.002

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  16 in total

1.  Cannabinoid CB(2) receptor attenuates morphine-induced inflammatory responses in activated microglial cells.

Authors:  Stefania Merighi; Stefania Gessi; Katia Varani; Debora Fazzi; Prisco Mirandola; Pier Andrea Borea
Journal:  Br J Pharmacol       Date:  2012-08       Impact factor: 8.739

Review 2.  Morphine: double-faced roles in the regulation of tumor development.

Authors:  X Y Zhang; Y X Liang; Y Yan; Z Dai; H C Chu
Journal:  Clin Transl Oncol       Date:  2017-11-10       Impact factor: 3.405

3.  Morphine inhibits cell viability and growth via suppression of vascular endothelial growth factor in human oral cancer HSC-3 cells.

Authors:  Tadashi Nishiwada; Yoshitaka Kawaraguchi; Keiko Uemura; Masahiko Kawaguchi
Journal:  J Anesth       Date:  2019-05-02       Impact factor: 2.078

4.  Characterization of neuroprotective effects of biphalin, an opioid receptor agonist, in a model of focal brain ischemia.

Authors:  Li Yang; Kaushik Shah; Hezhen Wang; Vardan T Karamyan; Thomas J Abbruscato
Journal:  J Pharmacol Exp Ther       Date:  2011-08-19       Impact factor: 4.030

Review 5.  [Interaction of anesthetics and analgesics with tumor cells].

Authors:  A Bundscherer; M Malsy; D Bitzinger; B M Graf
Journal:  Anaesthesist       Date:  2014-04       Impact factor: 1.041

6.  Effects of morphine and fentanyl on 5-fluorouracil sensitivity in human colon cancer HCT116 cells.

Authors:  Yasumitsu Nomura; Yoshitaka Kawaraguchi; Hiroshi Sugimoto; Hitoshi Furuya; Masahiko Kawaguchi
Journal:  J Anesth       Date:  2013-10-05       Impact factor: 2.078

Review 7.  Chronic opioid therapy in long-term cancer survivors.

Authors:  A Carmona-Bayonas; P Jiménez-Fonseca; E Castañón; A Ramchandani-Vaswani; R Sánchez-Bayona; A Custodio; D Calvo-Temprano; J A Virizuela
Journal:  Clin Transl Oncol       Date:  2016-07-21       Impact factor: 3.405

8.  Neuroprotective potential of biphalin, multireceptor opioid peptide, against excitotoxic injury in hippocampal organotypic culture.

Authors:  Maria Kawalec; Joanna E Kowalczyk; Malgorzata Beresewicz; Andrzej W Lipkowski; Barbara Zablocka
Journal:  Neurochem Res       Date:  2011-08-13       Impact factor: 3.996

Review 9.  The role of morphine in regulation of cancer cell growth.

Authors:  Katarzyna Gach; Anna Wyrębska; Jakub Fichna; Anna Janecka
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-07-29       Impact factor: 3.000

10.  Effect of κ-opioid receptor agonist on the growth of non-small cell lung cancer (NSCLC) cells.

Authors:  N Kuzumaki; A Suzuki; M Narita; T Hosoya; A Nagasawa; S Imai; K Yamamizu; H Morita; H Nagase; Y Okada; H J Okano; J K Yamashita; H Okano; T Suzuki; M Narita
Journal:  Br J Cancer       Date:  2012-02-16       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.